Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2024 Financial Results on August 13, 2024
Marinus Pharmaceuticals (Nasdaq: MRNS), a company focused on developing innovative therapeutics for seizure disorders, has announced its plans to release second quarter 2024 financial results on August 13, 2024. The company will host a conference call at 8:30 a.m. E.T. on the same day to provide a business update and discuss the financial results. Investors can join the call using domestic (877-405-1242) or international (201-389-0852) dial-in numbers. A webcast of the call will also be available, and an archived version will be accessible on the Marinus website approximately two hours after the event concludes.
Marinus Pharmaceuticals (Nasdaq: MRNS), un'azienda focalizzata nello sviluppo di terapie innovative per i disturbi convulsivi, ha annunciato i piani per rilasciare i risultati finanziari del secondo trimestre 2024 il 13 agosto 2024. L'azienda ospiterà una conferenza telefonica alle 8:30 a.m. E.T. dello stesso giorno per fornire aggiornamenti aziendali e discutere i risultati finanziari. Gli investitori possono partecipare alla chiamata utilizzando i numeri di accesso domestici (877-405-1242) o internazionali (201-389-0852). Sarà disponibile anche una trasmissione in diretta della chiamata, e una versione archiviata sarà accessibile sul sito di Marinus circa due ore dopo la conclusione dell'evento.
Marinus Pharmaceuticals (Nasdaq: MRNS), una empresa centrada en el desarrollo de terapias innovadoras para trastornos convulsivos, ha anunciado sus planes para publicar los resultados financieros del segundo trimestre de 2024 el 13 de agosto de 2024. La empresa llevará a cabo una llamada telefónica de conferencia a las 8:30 a.m. E.T. el mismo día para proporcionar una actualización del negocio y discutir los resultados financieros. Los inversores pueden unirse a la llamada utilizando números de acceso nacionales (877-405-1242) o internacionales (201-389-0852). También estará disponible una transmisión del evento, y una versión archivada podrá accederse en el sitio web de Marinus aproximadamente dos horas después de que finalice el evento.
Marinus Pharmaceuticals (Nasdaq: MRNS)는 발작 장애를 위한 혁신적인 치료제를 개발하는 데 중점을 둔 회사로, 2024년 2분기 재무 결과를 2024년 8월 13일에 발표할 계획이라고 발표했습니다. 회사는 같은 날 오전 8시 30분 E.T.에 비즈니스 업데이트를 제공하고 재무 결과를 논의하기 위한 컨퍼런스 콜을 개최할 예정입니다. 투자자들은 국내 전화 번호(877-405-1242) 또는 국제 전화 번호(201-389-0852)를 사용하여 전화를 참여할 수 있습니다. 또한, 콜의 웹 캐스트도 제공되며, 이벤트 종료 약 두 시간 후에 Marinus 웹사이트에서 아카이브된 버전이 접근 가능합니다.
Marinus Pharmaceuticals (Nasdaq: MRNS), une entreprise axée sur le développement de thérapies innovantes pour les troubles convulsifs, a annoncé ses plans de publication des résultats financiers du deuxième trimestre 2024 le 13 août 2024. L'entreprise organisera une conférence téléphonique à 8h30 E.T. ce même jour pour fournir une mise à jour sur les affaires et discuter des résultats financiers. Les investisseurs peuvent rejoindre l'appel en utilisant les numéros d'appel nationaux (877-405-1242) ou internationaux (201-389-0852). Un webinaire de l'appel sera également disponible, et une version archivée sera accessible sur le site Web de Marinus environ deux heures après la fin de l'événement.
Marinus Pharmaceuticals (Nasdaq: MRNS), ein Unternehmen, das sich auf die Entwicklung innovativer Therapeutika für Anfallsstörungen konzentriert, hat seine Pläne angekündigt, die Finanzergebnisse für das zweite Quartal 2024 am 13. August 2024 zu veröffentlichen. Das Unternehmen wird am selben Tag um 8:30 Uhr E.T. eine Telefonkonferenz abhalten, um ein Geschäftsun/update zu geben und die Finanzergebnisse zu besprechen. Investoren können an dem Anruf über nationale (877-405-1242) oder internationale (201-389-0852) Telefonnummern teilnehmen. Auch ein Webcast des Anrufs wird zur Verfügung stehen, und eine archivierte Version wird etwa zwei Stunden nach Abschluss des Ereignisses auf der Marinus-Website zugänglich sein.
- None.
- None.
Tuesday, August 13, 8:30 a.m. E.T.
Domestic: (877) 405-1242
International: (201) 389-0852
Webcast Registration: Click Here
An archived version of the call will be available approximately two hours after the completion of the event on the Marinus website at ir.marinuspharma.com/events-and-presentations.
About Marinus Pharmaceuticals
Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company first introduced FDA-approved prescription medication ZTALMY® (ganaxolone) oral suspension CV in the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240730576206/en/
Company
Investors
Sonya Weigle
SVP, IR, HR & Corporate Affairs
Marinus Pharmaceuticals, Inc.
sweigle@marinuspharma.com
Media
Molly Cameron
Director, Corporate Communications & Investor Relations
Marinus Pharmaceuticals, Inc.
mcameron@marinuspharma.com
Source: Marinus Pharmaceuticals
FAQ
When will Marinus Pharmaceuticals (MRNS) release its Q2 2024 financial results?
What time is the Marinus Pharmaceuticals (MRNS) Q2 2024 earnings call scheduled for?
How can investors access the Marinus Pharmaceuticals (MRNS) Q2 2024 earnings call?
Where can investors find the archived version of Marinus Pharmaceuticals' (MRNS) Q2 2024 earnings call?
